Trial Profile
A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2018
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Cognition disorders; Down syndrome
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 14 Mar 2017 New trial record